益气复脉联合左西孟旦治疗缺血性心肌病心力衰竭的临床效果及预后观察  

Clinical efficacy and prognostic observation of Yiqi Fumai combined with levosimendan in the treatment of ischemic cardiomyopathy with heart failure

作　　者：刘书文 孟娜 闻静 吴立巍 孙丽艳 LIU Shuwen;MENG Na;WEN Jing;WU Liwei;SUN Liyan(DepartmentⅢof Cardiology,Harbin Fourth Hospital,Heilongjiang,Harbin 150026,China;Department of Medical Insurance,Harbin Fourth Hospital,Heilongjiang,Harbin 150026,China;Department of Personnel,Harbin Fourth Hospital,Heilongjiang,Harbin 150026,China)

机构地区：[1]哈尔滨市第四医院心内三科,黑龙江哈尔滨150026 [2]哈尔滨市第四医院医保科,黑龙江哈尔滨150026 [3]哈尔滨市第四医院人事科,黑龙江哈尔滨150026

出　　处：《中国医药科学》2024年第22期118-121,共4页China Medicine And Pharmacy

基　　金：黑龙江省卫生健康委科研课题(20220303010732)。

摘　　要：目的探讨益气复脉联合左西孟旦治疗缺血性心肌病心力衰竭患者的临床效果及预后。方法选取2022年1月至2023年6月哈尔滨市第四医院收治的120例缺血性心肌病心力衰竭患者作为研究对象,采用随机数表法将其分为对照组60例、观察组60例。对照组在常规抗心力衰竭治疗基础上给予左西孟旦治疗,观察组在常规抗心力衰竭治疗基础上给予左西孟旦+益气复脉治疗。比较两组心脏超声指标、6 min步行试验(6MWT)、氨基末端脑钠肽前体(NT-proBNP)水平、不良反应及短期预后。结果治疗7 d后,观察组左心室射血分数(LVEF)高于对照组,左室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)低于对照组,差异有统计学意义(P<0.05)。治疗7 d后,观察组NT-proBNP低于对照组,6MWT步行距离长于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。随访6个月期间,观察组因心力衰竭再住院率及病死率低于对照组,差异有统计学意义(P<0.05)。结论益气复脉联合左西孟旦可有效改善缺血性心肌病心力衰竭患者心功能,安全性良好,且可明显改善患者短期预后。Objective To investigate the clinical efficacy and prognosis of Yiqi Fumai combined with levosimendan in the treatment of ischemic cardiomyopathy with heart failure.Methods A total of 120 patients with ischemic cardiomyopathy and heart failure admitted to Harbin Fourth Hospital from January 2022 to June 2023 were selected as the research subjects.They were randomly divided into a control group(n=60,treated with levosimendan)and an observation group(n=60,treated with levosimendan+Yiqi Fumai)using a random number list method.Echocardiographic indices,six-minute walking experiment(6MWT),N-terminal pro-B-type natriuretic peptide(NT-proBNP)levels,adverse reactions(ADRs)and short-term prognosis were compared between the two groups.Results After 7 days of treatment,the observation group showed more significant improvements in left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD),and left ventricular end diastolic diameter(LVEDD)compared to the control group(P<0.05).After 7 days of treatment,the observation group showed better improvement in NT proBNP and 6MWT walking distance compared to the control group(P<0.05).There was no statistically significant difference in the incidence of ADRs between the two groups(P>0.05).During the 6-month follow-up,the readmission rate and mortality rate of the observation group were lower than those of the control group(P<0.05).Conclusion Yiqi fumai combined with levosimendan can effectively improve the cardiac function of patients with ischemic cardiomyopathy and heart failure,with good safety,and can obviously improve the short-term prognosis of patients.

关 键 词：益气复脉 左西孟旦 缺血性心肌病 心力衰竭 心功能 预后 

分 类 号：R542.2[医药卫生—心血管疾病]